LUMOXITI is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Innate Pharma, Inc.. The primary component is Moxetumomab Pasudotox.
| Product ID | 73380-4700_50a54d82-8f62-4e80-a35f-cd51a48bb0e5 |
| NDC | 73380-4700 |
| Product Type | Human Prescription Drug |
| Proprietary Name | LUMOXITI |
| Generic Name | Moxetumomab Pasudotox |
| Dosage Form | Injection, Powder, Lyophilized, For Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2020-05-15 |
| Marketing Category | BLA / BLA |
| Application Number | BLA761104 |
| Labeler Name | Innate Pharma, Inc. |
| Substance Name | MOXETUMOMAB PASUDOTOX |
| Active Ingredient Strength | 1 mg/mL |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2020-05-15 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA761104 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2020-05-15 |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0310-4700 | LUMOXITI | moxetumomab pasudotox |
| 73380-4700 | LUMOXITI | MOXETUMOMAB PASUDOTOX |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() LUMOXITI 87778486 5610169 Live/Registered |
INNATE PHARMA S.A. 2018-01-31 |